Completed PHASE2 INTERVENTIONAL NCT00003731

Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Brain and Central Nervous System Tumors

Updated 5 times since 2017 Last updated: Sep 20, 2012 Started: Dec 31, 1998 Primary completion: Jan 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003731, this PHASE2 trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 5 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Organisation for Research and Treatment of Cancer - EORTC

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Bamberg, Germany , Basel, Switzerland , Berlin, Germany , Bern, Switzerland , Bratislava, Slovakia , Brussels, Belgium , Edinburgh, United Kingdom , Lausanne, Switzerland , Leuven, Belgium and 12 more locations